About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Although several years have passed since health savings accounts became available to Americans, the number of enrollees has remained relatively low. This article explores some of the pitfalls of the plans and the reluctance of the public to climb aboard.
P&T Around the world
The authors present an update to an earlier P&T article on the embargo of Priorix measles–mumps–rubella vaccine after a deadly health scare in Ho Chi Minh City.
Peter Teichman, MD, and Nguyen Tri Doan, MD
Considerations Associated with Therapeutic Interchange within the Fluoroquinolone Class of Antimicrobials
The author discusses the procedures, safeguards, and costs involved when less expensive agents replace preferred drugs in the same pharmacological class.
Robert P. Rapp, PharmD, FCCP
The authors describe the changes in the prescribing patterns for NSAIDs that resulted when valdecoxib (Bextra) and rofecoxib (Vioxx) were withdrawn from the market.
Molly T. Vogt, PhD, Bethany Fedutes-Henderson, PharmD, Amit Duggal, PharmD, MPH, Nicole T. Ansani, PharmD, John Gillespie, MD, and Terence Starz, MD
Author: Robert L. Shook
Reviewed by Burton Orland, BS, RPh
Sitagliptin/metformin (Janumet) for diabetes, lapatinib (Tykerb) for HER-2–positive breast cancer, and protein C concentrate powder (Ceprotin) for venous disorders are reviewed.
Marvin M. Goldenberg, PhD, RPh, MS
David Nash, MD, MBA, reports on the results of a BlueCross BlueShield survey on how consumers use the Internet to obtain information about medical treatments.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains the potential problems that can result when new medication protocols are implemented too quickly.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses forthcoming changes to two laws calling for pediatric drug-testing trials.
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Dr. Paris Abrams and Dr. Nino Marzella review dabigatran (Rendix), a direct thrombin inhibitor.
Paris Abrams, PharmD, and Nino Marzella, BS, PharmD